-
1
-
-
11244296162
-
Mechanisms of tamoxifen resistance
-
10.1677/erc.1.00776, 15613444
-
Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 2004, 11:643-658. 10.1677/erc.1.00776, 15613444.
-
(2004)
Endocr Relat Cancer
, vol.11
, pp. 643-658
-
-
Ring, A.1
Dowsett, M.2
-
2
-
-
43249130208
-
Double-blind, randomised placebo controlled trial of fulvestrant compared with exemestane after prior non-steroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor positive advanced breast cancer: results form EFECT
-
10.1200/JCO.2007.13.5822, 18316794
-
Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, Fein L, Romieu G, Buzdar A, Robertson JF, Brufsky A, Possinger K, Rennie P, Sapunar F, Lowe E, Piccart M. Double-blind, randomised placebo controlled trial of fulvestrant compared with exemestane after prior non-steroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor positive advanced breast cancer: results form EFECT. J Clin Oncol 2008, 26:1664-1670. 10.1200/JCO.2007.13.5822, 18316794.
-
(2008)
J Clin Oncol
, vol.26
, pp. 1664-1670
-
-
Chia, S.1
Gradishar, W.2
Mauriac, L.3
Bines, J.4
Amant, F.5
Federico, M.6
Fein, L.7
Romieu, G.8
Buzdar, A.9
Robertson, J.F.10
Brufsky, A.11
Possinger, K.12
Rennie, P.13
Sapunar, F.14
Lowe, E.15
Piccart, M.16
-
3
-
-
0042232592
-
Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation
-
10.1074/jbc.M305226200, 12775708
-
Martin LA, Farmer I, Johnston SR, Ali S, Marshall C, Dowsett M. Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 2003, 278:30458-30468. 10.1074/jbc.M305226200, 12775708.
-
(2003)
J Biol Chem
, vol.278
, pp. 30458-30468
-
-
Martin, L.A.1
Farmer, I.2
Johnston, S.R.3
Ali, S.4
Marshall, C.5
Dowsett, M.6
-
4
-
-
0032887942
-
Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer
-
10.1677/erc.0.0060373, 10516852
-
Nicholson RI, McClelland RA, Robertson JF, Gee JM. Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer 1999, 6:373-387. 10.1677/erc.0.0060373, 10516852.
-
(1999)
Endocr Relat Cancer
, vol.6
, pp. 373-387
-
-
Nicholson, R.I.1
McClelland, R.A.2
Robertson, J.F.3
Gee, J.M.4
-
5
-
-
0035971181
-
Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance
-
10.1074/jbc.M010840200, 11139588
-
Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 2001, 276:9817-9824. 10.1074/jbc.M010840200, 11139588.
-
(2001)
J Biol Chem
, vol.276
, pp. 9817-9824
-
-
Campbell, R.A.1
Bhat-Nakshatri, P.2
Patel, N.M.3
Constantinidou, D.4
Ali, S.5
Nakshatri, H.6
-
6
-
-
34548537574
-
A phase II placebo-controlled trial of neo-adjuvant anastrozole alone or with gefitinib in early breast cancer
-
10.1200/JCO.2006.09.6578, 17679728
-
Smith IE, Walsh G, Skene A, Llombart A, Mayordomo JI, Detre S, Salter J, Clark E, Magill P, Dowsett M. A phase II placebo-controlled trial of neo-adjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol 2007, 25:3816-3822. 10.1200/JCO.2006.09.6578, 17679728.
-
(2007)
J Clin Oncol
, vol.25
, pp. 3816-3822
-
-
Smith, I.E.1
Walsh, G.2
Skene, A.3
Llombart, A.4
Mayordomo, J.I.5
Detre, S.6
Salter, J.7
Clark, E.8
Magill, P.9
Dowsett, M.10
-
7
-
-
79952259688
-
Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study
-
10.1158/1078-0432.CCR-10-1869, 3074404, 21220480
-
Osborne CK, Neven P, Dirix LY, Mackey JR, Robert J, Underhill C, Schiff R, Gutierrez C, Migliaccio I, Anagnostou VK, Rimm DL, Magill P, Sellers M. Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res 2011, 17:1147-1159. 10.1158/1078-0432.CCR-10-1869, 3074404, 21220480.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 1147-1159
-
-
Osborne, C.K.1
Neven, P.2
Dirix, L.Y.3
Mackey, J.R.4
Robert, J.5
Underhill, C.6
Schiff, R.7
Gutierrez, C.8
Migliaccio, I.9
Anagnostou, V.K.10
Rimm, D.L.11
Magill, P.12
Sellers, M.13
-
8
-
-
77949754385
-
Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer
-
10.1158/1078-0432.CCR-09-2282, 20215537
-
Cristofanilli M, Valero V, Mangalik A, Royce M, Rabinowitz I, Arena FP, Kroener JF, Curcio E, Watkins C, Bacus S, Cora EM, Anderson E, Magill PJ. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin Cancer Res 2010, 16:1904-1914. 10.1158/1078-0432.CCR-09-2282, 20215537.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 1904-1914
-
-
Cristofanilli, M.1
Valero, V.2
Mangalik, A.3
Royce, M.4
Rabinowitz, I.5
Arena, F.P.6
Kroener, J.F.7
Curcio, E.8
Watkins, C.9
Bacus, S.10
Cora, E.M.11
Anderson, E.12
Magill, P.J.13
-
9
-
-
73149115341
-
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone-receptor-positive metastatic breast cancer
-
10.1200/JCO.2009.23.3734, 19786658
-
Johnston S, Pippen J, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone-receptor-positive metastatic breast cancer. J Clin Oncol 2009, 27:5538-5846. 10.1200/JCO.2009.23.3734, 19786658.
-
(2009)
J Clin Oncol
, vol.27
, pp. 5538-5846
-
-
Johnston, S.1
Pippen, J.2
Pivot, X.3
Lichinitser, M.4
Sadeghi, S.5
Dieras, V.6
Gomez, H.L.7
Romieu, G.8
Manikhas, A.9
Kennedy, M.J.10
Press, M.F.11
Maltzman, J.12
Florance, A.13
O'Rourke, L.14
Oliva, C.15
Stein, S.16
Pegram, M.17
-
10
-
-
73949105921
-
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results form the randomized TAnDEM study
-
10.1200/JCO.2008.20.6847, 19786670
-
Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova A, Révil C, Jones A. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results form the randomized TAnDEM study. J Clin Oncol 2009, 27:5529-5537. 10.1200/JCO.2008.20.6847, 19786670.
-
(2009)
J Clin Oncol
, vol.27
, pp. 5529-5537
-
-
Kaufman, B.1
Mackey, J.R.2
Clemens, M.R.3
Bapsy, P.P.4
Vaid, A.5
Wardley, A.6
Tjulandin, S.7
Jahn, M.8
Lehle, M.9
Feyereislova, A.10
Révil, C.11
Jones, A.12
-
11
-
-
84863078767
-
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer
-
Baselga J, Campone M, Piccart M, Burris HA 3, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012, 366:520-529.
-
(2012)
N Engl J Med
, vol.366
, pp. 520-529
-
-
Baselga, J.1
Campone, M.2
Piccart, M.3
Burris HA, 3.4
Rugo, H.S.5
Sahmoud, T.6
Noguchi, S.7
Gnant, M.8
Pritchard, K.I.9
Lebrun, F.10
Beck, J.T.11
Ito, Y.12
Yardley, D.13
Deleu, I.14
Perez, A.15
Bachelot, T.16
Vittori, L.17
Xu, Z.18
Mukhopadhyay, P.19
Lebwohl, D.20
Hortobagyi, G.N.21
more..
-
12
-
-
79951814007
-
TAMRAD: a GINECO randomized phase II trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to aromatase inhibitors (AI)
-
Abstract S1-6
-
Bachelot T, Bourgier C, Cropet C, Guastalla J-P, Ferrero J-M, Leger-Falandry C, Soulie P, Eymard J-C, Debled M, Spaeth D, Legouffe E, Delozier T, El Kouri C, Chidiac J. TAMRAD: a GINECO randomized phase II trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to aromatase inhibitors (AI). Cancer Res 2010, 70(Suppl 2). Abstract S1-6.
-
(2010)
Cancer Res
, vol.70
, Issue.SUPPL. 2
-
-
Bachelot, T.1
Bourgier, C.2
Cropet, C.3
Guastalla, J.-P.4
Ferrero, J.-M.5
Leger-Falandry, C.6
Soulie, P.7
Eymard, J.-C.8
Debled, M.9
Spaeth, D.10
Legouffe, E.11
Delozier, T.12
El Kouri, C.13
Chidiac, J.14
-
13
-
-
34447106387
-
Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer
-
Abs 6091
-
CChow LWC, Sun Y, Jassem J, Baselga J, Hayes DF, Wolff AC, Hachemi S, Cincotta M, Yu BW, Kong S, Moore L. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2006, 100(Suppl 1). Abs 6091.
-
(2006)
Breast Cancer Res Treat
, vol.100
, Issue.SUPPL. 1
-
-
CChow, L.W.C.1
Sun, Y.2
Jassem, J.3
Baselga, J.4
Hayes, D.F.5
Wolff, A.C.6
Hachemi, S.7
Cincotta, M.8
Yu, B.W.9
Kong, S.10
Moore, L.11
-
14
-
-
60549089850
-
Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen
-
10.1158/0008-5472.CAN-08-0857, 2644349, 19190349
-
Sabnis G, Schavowitz A, Goloubeva O, Macedo LF, Brodie A. Trastuzumab reverses letrozole resistance and amplifies the sensitivity of breast cancer cells to estrogen. Cancer Res 2009, 69:1416-1428. 10.1158/0008-5472.CAN-08-0857, 2644349, 19190349.
-
(2009)
Cancer Res
, vol.69
, pp. 1416-1428
-
-
Sabnis, G.1
Schavowitz, A.2
Goloubeva, O.3
Macedo, L.F.4
Brodie, A.5
-
15
-
-
66849136781
-
Phase II randomised study of neo-adjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer
-
10.1200/JCO.2008.18.8391, 19380449
-
Baselga J, Semiglazov V, van Dam P, Manikhas A, Bellet M, Mayordomo J, Campone M, Kubista E, Greil R, Bianchi G, Steinseifer J, Molloy B, Tokaji E, Gardner H, Phillips P, Stumm M, Lane HA, Dixon JM, Jonat W, Rugo HS. Phase II randomised study of neo-adjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009, 27:2630-2637. 10.1200/JCO.2008.18.8391, 19380449.
-
(2009)
J Clin Oncol
, vol.27
, pp. 2630-2637
-
-
Baselga, J.1
Semiglazov, V.2
van Dam, P.3
Manikhas, A.4
Bellet, M.5
Mayordomo, J.6
Campone, M.7
Kubista, E.8
Greil, R.9
Bianchi, G.10
Steinseifer, J.11
Molloy, B.12
Tokaji, E.13
Gardner, H.14
Phillips, P.15
Stumm, M.16
Lane, H.A.17
Dixon, J.M.18
Jonat, W.19
Rugo, H.S.20
more..
|